Epigenetic therapies are mechanistically justified by IDH1/2-induced elevations in DNA and histone methylation; however, IDH-mutated dedifferentiated chronic lymphocytic leukemia (CS) displays reduced hypermethylation and distinct loci compared with IDH-mutated conventional CS [193]. Here, IDH2 is linked to B-cell chronic lymphocytic leukemia.